News | Cath Lab | October 17, 2017

Societies Issue New Performance and Quality Measures for Treating Heart Attack Patients

Updated measures promote quality care for STEMI, NSTEMI patients

Societies Issue New Performance and Quality Measures for Treating Patients with Heart Attack

October 17, 2017 — The American College of Cardiology and the American Heart Association recently released updated clinical performance and quality measures to benchmark and improve the quality of care for adult patients hospitalized with ST-elevation and non–ST-elevation myocardial infarction (STEMI and NSTEMI, respectively).

Acute myocardial infarction (AMI) is a frequent cause of hospital admission in the United States and is associated with significant short- and long-term mortality and morbidity. The rates of hospitalization and 30-day mortality for AMI have been on the decline, likely due to the shift in the pattern of clinical presentation of AMI as well as to improved acute treatments and long-term care. However, AMI patients who survive the initial event still have substantial risk for future cardiovascular events, including recurrent MI, death, heart failure and stroke.

This new measure set, which updates the 2008 measure set to reflect the "2014 AHA/ACC Guideline for the Management of Patients with Non-ST-Elevation Acute Coronary Syndromes" and the 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction," includes 24 total measures, of which 17 are performance measures and seven are quality measures. The document includes 11 new measures and addresses various care domains including: effective clinical care, communication and care coordination, efficiency and cost reduction, patient safety, community, population and public health, and also includes new patient safety quality measures.

“Implementation of this measure set by healthcare providers, physician practices and hospital systems will enhance the quality of care and likely improve outcomes of patients hospitalized with a heart attack,” said Hani Jneid, M.D., FACC, FAHA, director of interventional cardiology research at Baylor College of Medicine, director of interventional cardiology at the Michael E. DeBakey Medical Center VA Medical Center in Houston and the chair of the writing committee for the measures.

In developing the new measure set, the writing committee reviewed recent clinical practice guidelines and other clinical guidance documents. The committee also examined available information on disparities in care to address which new measures might be appropriate as performance versus quality measures for this update. The writing committee discussed which measures should be revised to reflect the updated science and worked to identify which guideline recommendations could serve as the basis for new performance or quality measures.

The document emphasizes the importance of timeliness of reperfusion therapy for STEMI patients with four dedicated measures: door-to-needle time, first medical contact-device time, door-in-door-out time, and time to primary percutaneous coronary intervention (PCI) among transferred patients. The measures also underscore the importance of treating all AMI patients with dual antiplatelet therapies, as long as there are no contraindications.

“The writing committee acknowledges that the new measures created in this set will need to be tested and validated over time,” Jneid said. “By publishing this performance and quality measure set, we hope to encourage their widespread and expeditious adoption, as well as facilitate the collection and analysis of data needed to continuously assess their relevance over time.”

In the future, the writing committee members anticipate having data that will allow them to reassess whether any of the measures included in this set should be revised.

The "2017 AHA/ACC Clinical Performance and Quality Measures for Adults With ST-Elevation and Non–ST-Elevation Myocardial Infarction" was published in the Journal of the American College of Cardiology and Circulation.

For more information: www.onlinejacc.org

 

Reference:

1. Hani Jneid, Daniel Addison, Deepak L. Bhatt, et al. “2017 AHA/ACC Clinical Performance and Quality Measures for Adults With ST-Elevation and Non–ST-Elevation Myocardial Infarction.” JACC. Volume 70, Issue 16, October 2017 DOI: 10.1016/j.jacc.2017.06.032
 

Related Content

Teleflex Launches Next-Generation Sympro Elite and Expro Elite Snares
Technology | Cath Lab | February 07, 2018
Teleflex Inc. has announced 510(k) clearance by the U.S. Food and Drug Administration (FDA) and U.S. commercial launch...
SCAI Advocacy Committee Highlights Reimbursement Reform Efforts in 2017
News | Cath Lab | January 30, 2018
The Society for Cardiovascular Angiography and Interventions (SCAI) highlighted the efforts of its Advocacy Committee...
IAC Releases Cardiovascular Catheterization Accreditation Program
News | Cath Lab | January 25, 2018
January 25, 2018 – The Intersocietal Accreditation Commission (IAC) announced the release of its Cardiovascular Cathe
Videos | Cath Lab | January 04, 2018
Bernadette Speiser, BSN, MSN, CCRN, RCIS, a cardiac cath/EP nurse at Palo Alto Veterans Hospital, Palo Alto, Calif.,
FDA Initiates Class I Recall of Sterilmed Reprocessed Agilis Steerable Introducer Sheath
News | Cath Lab | January 04, 2018
The U.S. Food and Drug Administration (FDA) announced a Class I recall of Sterilmed’s Agilis Steerable Introducer...
The California Heart & Vascular Clinic in El Centro, Calif., treated the first post-FDA clearance patient with a DABRA atherectomy system. Athar Ansari, M.D.

The California Heart & Vascular Clinic in El Centro, Calif., treated the first post-FDA clearance patient with a DABRA system. 

Feature | Cath Lab | November 24, 2017 | Athar Ansari, M.D., FACC
As debates about the current state and future of healthcare rage in Congress, the media and healthcare settings acros
Videos | Cath Lab | November 08, 2017
Juan Granada, M.D., Cardiovascular Research Foundation president and chief executive officer, shares his insights on
Results of the ORBITA study found no difference in exercise time after six weeks in patients with stable angina who received percutaneous coronary intervention (PCI) versus a placebo treatment. TCT 2017
Feature | Cath Lab | November 06, 2017
November 6, 2017 – Results from ORBITA, a prospective multi-center randomized blinded placebo-controlled study, found
Culprit Lesion-Only PCI Improves Outcomes for Cardiogenic Shock Patients Compared to Multivessel PCI
News | Cath Lab | November 01, 2017
November 1, 2017 — Results from the prospective, randomized, multicenter CULPRIT-SHOCK trial found an initial strateg
Overlay Init